Glytec Presents Several Research Studies at the ADA 75th Scientific Sessions

JUNE 8, 2015

Glytec Presents Several Research Studies at the ADA 75th Scientific Sessions

Data continue to validate the benefits of standardized glycemic management through computerized decision support for both IV and subcutaneous insulin dosing.

Boston, MA — Glytec, the pioneer and leader in providing innovative, FDA-cleared glucose management software solutions central to effective diabetes management, today announced that several abstracts featuring the company’s eGlycemic Management Solution® (eGMS®) have been selected as poster presentations at the American Diabetes Association 75th Scientific Sessions. The 75th Scientific Sessions, taking place from June 5-9th in Boston, are the premier venue for exchanging news and showcasing innovation to the diabetes community.

At the conference, Glytec will be displaying proven results of improved subcutaneous and IV insulin management using Glytec’s eGMS®. eGMS® provides clinican-developed, algorithm-based software (Glucommander™) designed to considered insulin sensitivity and individualize dosing recommendations to address and prevent excursions through all aspects of insulin therapy.

“The ADA brings together the best and most innovative research to improve care for patients with diabetes, and we were honored to be able to present several clinical studies at the 2015 meeting,” said Raymie McFarland, Vice President of Quality Initiatives at Glytec. “Reducing the incidence of hypoglycemia during insulin treatment is critically important, yet often difficult to achieve, especially with certain patient populations. This latest round of studies focused on patients with end stage renal disease, kidney transplant, stress or medication induced hyperglycemia without diabetes, and patients undergoing bone marrow transplant.”

The following scientific posters will be presented at the conference:

“The treatment of steroid-induced hyperglycemia during graft vs. host disease in bone marrow transplant patients on the surface seems like it would be important. Up until now, most thought it would be difficult to even consider a clinical trial to assess if glucose control could impact outcomes – including mortality – because our insulin protocols were not robust enough to deal with the high-dose steroids, TPN, and occasional eating all at the same time,” said Irl B. Hirsch, MD, Professor of Medicine at University of Washington Medical Center – Roosevelt. “The Glucommander showed in our feasibility trial it is indeed possible to control glycemia in this population.”

About Glytec

Founded in 2006, Glytec is a rapidly growing digital heath company specializing in advanced technology for diabetes management. eGMS®, Glytec’s glycemic management information system, enables providers, payers and patients to significantly reduce the frequency, risks and costs of hyperglycemia and hypoglycemia. The cloud based, modular eGMS® centers on the Glucommander™ Suite of FDA-cleared, predictive dosing algorithms for IV, subcutaneous and pediatric dosing: Glucommander™ IV (FDA clearance 2006), Glucommander™ SubQ (FDA clearance 2010) and Glucommander™ Pediatrics (FDA clearance 2012). Comprehensive management of patients requiring insulin therapy is further enabled by seamless EHR integration (SmartClick) and robust analytics (Glucometrics) and surveillance (GlucoSurveillance) capabilities. The unique breadth and depth of the eGMS®* interventional clinical decision support tools allows providers to standardize its process and individualize treatment across all areas of care, and is proven to result in significant improvements in clinical and financial outcomes versus traditional methods. For more information, please visit

*Multiple patents pending

View on Business Wire